Skip to main content

Advertisement

SpringerLink
Log in

Management of antiretroviral therapy in neonates, children, and adolescents

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

There have been tremendous advances in the prevention of maternal-to-child transmission of HIV and treatment of HIV-infected children and adolescents. Although multiple classes of anti-HIV drugs are available that can control viral replication and stabilize immune function when used in combination, patients and their providers must also manage complex and frequently toxic regimens. This article updates our original report that summarizes official National Institutes of Health guidelines for the prevention of perinatal HIV infection and the management of pediatric and adolescent HIV infection and provides the most current updates on indications for therapy, recommended first-line therapy, criteria for changing therapy, salvage therapy, novel management strategies, and a comprehensive summary of available antiretroviral agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Neely M, Kovacs A: Management of antiretroviral therapy in neonates, children, and adolescents. Curr Infect Dis Rep 2003, 5:521–530.

    PubMed  Google Scholar 

  2. AIDS epidemic update: December 2003, Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). http://www.who.int/hiv/facts/ epiupdate_en.pdf. Accessed March 11, 2004.

  3. Bulterys M, Nolan ML, Jamieson D: Advances in the prevention of mother-to-child HIV-1 transmission: current issues, future challenges. AIDScience 2002, 2.

  4. Young people at risk: HIV/AIDS among America’s youth. Centers for Disease Control. http://www.cdc.gov/hiv/pubs/ facts/youth.htm. Accessed March 11, 2004.

  5. Guidelines for the use of antiretroviral agents in pediatric HIV infection, US Department of Health and Human Services. http://www.aidsinfo.nih.gov. Accessed March 9, 2004.

  6. Burns DN, Mofenson LM: Paediatric HIV-1 infection. Lancet 1999, 354(Suppl 2):SII1-SII6.

    Article  PubMed  Google Scholar 

  7. Cooper ER, Charurat M, Mofenson L, et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002, 29:484–494.

    PubMed  CAS  Google Scholar 

  8. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173–1180.

    Article  PubMed  CAS  Google Scholar 

  9. Cooper ER, Nugent RP, Diaz C, et al.: After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis 1996, 174:1207–1211.

    PubMed  CAS  Google Scholar 

  10. Dorenbaum A, Cunningham CK, Gelber RD, et al.: Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002, 288:189–198.

    Article  PubMed  CAS  Google Scholar 

  11. Mofenson LM, Lambert JS, Stiehm ER, et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999, 341:385–393.

    Article  PubMed  CAS  Google Scholar 

  12. Johnson VA, Petropoulos CJ, Woods CR, et al.: Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001, 183:1688–1693.

    Article  PubMed  CAS  Google Scholar 

  13. Eshleman SH, Becker-Pergola G, Deseyve M, et al.: Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). J Infect Dis 2001, 184:914–917.

    Article  PubMed  CAS  Google Scholar 

  14. Cunningham CK, Chaix ML, Rekacewicz C, et al.: Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002, 186:181–188.

    Article  PubMed  CAS  Google Scholar 

  15. Eshleman SH, Mracna M, Guay LA, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001, 15:1951–1957.

    Article  PubMed  CAS  Google Scholar 

  16. Kovacs A, Husson R, Cowles K, et al.: Genotypic resistance to zidovudine and didanosine among early treated infants in ACTG 239 [abstract]. Paper presented at the 39th Annual Meeting of Infectious Diseases Society of America. San Francisco, CA; October, 2001.

  17. US Department of Health and Human Services: Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States-November 26, 2003. http://www.aidsinfo. nih.gov/guidelines. Accessed December 6, 2003.

  18. Bulterys M, Jamieson D, O’Sullivan MJ, et al.: Performance of rapid HIV-1 testing at labor and delivery: a multicenter study [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  19. Hitti J, Frenkel LM, Huang S, et al.: Toxicity with continuous nevirapine in pregnancy: results from PACTG 1022 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  20. Luzuriaga K, McManus M, Catalina M, et al.: Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000, 74:6984–6991.

    Article  PubMed  CAS  Google Scholar 

  21. Bryson Y, Stek A, Mirochnick M, et al.: Pharmacokinetics (PK) antiviral activity and safety of nelfinavir (NFV) with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2 [abstract]. Paper presented at the 9th Conference on Retrovirus and Opportunistic Infections. Seattle, WA; February 24–28, 2002.

  22. Kourtis AP, Ibegbu C, Nahmias AJ, et al.: Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 1996, 335:1431–1436. [Published erratum appears in N Engl J Med 1997, 336:595.]

    Article  PubMed  CAS  Google Scholar 

  23. Mofenson LM, Korelitz J, Meyer WA, et al.: The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997, 175:1029–1038.

    Article  PubMed  CAS  Google Scholar 

  24. Palumbo PE, Raskino C, Fiscus S, et al.: Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998, 279:756–761.

    Article  PubMed  CAS  Google Scholar 

  25. Blanche S, Newell ML, Mayaux MJ, et al.: Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:442–450.

    PubMed  CAS  Google Scholar 

  26. Scott GB, Hutto C, Makuch RW, et al.: Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989, 321:1791–1796.

    Article  PubMed  CAS  Google Scholar 

  27. Kovacs A, Frederick T, Church J, et al.: CD4 T-lymphocyte counts and Pneumocystis carinii pneumonia in pediatric HIV infection. JAMA 1991, 265:1698–1703.

    Article  PubMed  CAS  Google Scholar 

  28. Kovacs A, Schluchter M, Easley K, et al.: Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999, 341:77–84.

    Article  PubMed  CAS  Google Scholar 

  29. Guidelines for the use of antiretroviral agents in HIVinfected adults and adolescents. US Department of Health and Human Services. http://www.aidsinfo.nih.gov. Accessed March 9, 2004. Important guidelines that represent the consensus opinion of experts in the management of adolescent and adult HIV infection.

  30. Saavedra J, McCoig C, Mallory M, et al.: Clinical experience with triple nucleoside combination ZDV/3TC/abacavir as initial therapy in HIV-infected children [abstract]. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology; 2001:348.

  31. Wells CJ, Sharland M, Smith CJ, et al.: Triple nucleoside analogue therapy with zidovudine, lamivudine and abacavir in the pediatric HIV London South Net (PHILS-NET) cohort [abstract]. Proceedings of the XIV International AIDS Conference. Barcelona: International AIDS Society; 2002:4625.

    Google Scholar 

  32. Important interim results from a phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095). Department of Health and Human Services. http://www.niaid.nih.gov/daids/pdf/aactg_a5095.pdf. Accessed June 8, 2003.

  33. Saez-Llorens X: Once-daily emtricitabine in HIV-infected pediatric patients with other antiretroviral agents [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.

  34. McKinney R, Rodman J, Rathore M, et al.: Extended follow-up and pharmacokinetics for once daily emtricitabine, didanosine and efavirenz for antiretroviral-naive children and adolescents [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  35. McKinney R, Sea RM: PACTG 1021: an ongoing phase I/II study of once-daily emtricitabine, didanosine, and efavirenz in therapy-naive or minimally treated pediatric patients [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.

  36. Bergshoeff A, Burger D, Farrelly L, et al.: Pharmacokinetics of once daily vs twice daily lamivudine and abacavir in HIV-1 infected children: PENTA 13 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  37. Wilson JW: Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS Read 2003, 13:25–28.

    PubMed  Google Scholar 

  38. Cohen NJ, Oram R, Elsen C, Englund JA: Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002, 21:647–653.

    Article  PubMed  Google Scholar 

  39. Servais J, Hainaut M, Schmitz V, et al.: Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor. Pediatr Infect Dis J 2002, 21:214–220.

    Article  PubMed  Google Scholar 

  40. Carpenter CC, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381–390.

    Article  PubMed  CAS  Google Scholar 

  41. The EuroGuidelines Group for HIV Resistance: Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001, 15:309–320.

    Article  Google Scholar 

  42. Little SJ, Daar ES, D’Aquila RT, et al.: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142–1149.

    Article  PubMed  CAS  Google Scholar 

  43. Church JA, Cunningham C, Hughes M, et al.: Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2002, 21:653–659.

    Article  PubMed  Google Scholar 

  44. Wiznia A, Church J, Stavola J, et al.: 24-week safety and efficacy of enfuvirtide as part of an optimized antiretroviral regimen in adolescents [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  45. Hazra R, Balis FM, Tullio AN, et al.: Single-dose and steadystate pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 2004, 48:124–129.

    Article  PubMed  CAS  Google Scholar 

  46. Tsai CC, Follis KE, Sabo A, et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995, 270:1197–1199.

    Article  PubMed  CAS  Google Scholar 

  47. Hazra R, Gafni R, Maldarelli F, et al.: Safety, tolerability, and clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  48. Gallant JE, Deresinski S: Tenofovir disoproxil fumarate. Clin Infect Dis 2003, 37:944–950.

    Article  PubMed  CAS  Google Scholar 

  49. Tarantal AF, Marthas ML, Shaw JP, et al.: Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:323–333.

    PubMed  CAS  Google Scholar 

  50. Badaro R, Dejesus CE, Lazzarin A, et al.: Efficacy and safety of atazanavir with ritonavir or saquinavir versus lopinavir and ritonavir in combination with tenofovir and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045 [abstract]. Paper presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–17, 2003.

  51. Nieto-Cisneros I, Zala C, Fessel J, et al.: Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with 2 NRTIs in patients who have experienced virologic failure with prior pi-containing regimen(s): 24-week results from BMS AI424-043 [abstract]. Paper presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–17, 2003.

  52. Kostman J, Grund B, Leduc R, et al.: A randomized trial of 1 or 2 protease inhibitors in combination with a non-nucleoside reverse transcriptase inhibitor and background therapy in patients with virologic failure on an initial protease inhibitor-containing regimen [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  53. Delaugerre C, Teglas JP, Treluyer JM, et al.: Predictive factors of virological success in PI-naive and experienced HIV-infected children treated with a regimen including lopinavir/ritonavir [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  54. Havens P, Frank M, Cuene B, et al.: Pharmacokinetics and safety of lopinavir/ritonavir doses greater than 300 mg/m2 in children and adolescents with HIV infection [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  55. Staszewski S, Dauer B, Von Hentig N, et al.: The LOPSAQ study: 24 week analysis of the double protease inhibitor (PI) salvage regimen containing lopinavir (LPV/R) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy [abstract]. Paper presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–15, 2003.

  56. Raguin G, Chene G, Morand-Joubert L, et al.: Salvage therapy with lopinavir/ritonavir, amprenavir +/− and additional boost with ritonavir: 1-year results of Puzzle 1-ANRS 104 Study [abstract]. Paper presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France; July 13–15, 2003.

  57. Low-Beer S, Yip B, O’Shaughnessy MV, et al.: Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000, 23:360–361.

    PubMed  CAS  Google Scholar 

  58. Jayaweera D, Tanner T, Nowak AM, et al.: Antiviral potency and tolerability of a convenient once a day direct observed therapy with amprenavir containing HAART regimen in antiretroviral naive, inner-city minority patients with poor HIV knowledge and very advanced AIDS [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain; July 7–12, 2002.

  59. Jayaweera D, Tanner T, Nowak AM, et al.: Direct observed therapy (DOT) in HIV: is it feasible in clinical practice? Problems associated with DOT an amprenavir containing HAART regimen in an antiretroviral-naive, inner-city minority patients with poor HIV knowledge and very advanced AIDS [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain; July 7–15, 2002.

  60. Khanlou H, Kandula VR, Yeh V, et al.: Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in an urban community-based institution. J Acquir Immune Defic Syndr 2003, 33:651–653.

    Article  PubMed  Google Scholar 

  61. Mitty JA, Stone VE, Sands M, et al.: Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002, 34:984–990.

    Article  PubMed  Google Scholar 

  62. Mitty JA, Macalino G, Taylor L, et al.: Directly observed therapy (DOT) for individuals with HIV: successes and challenges. MedGenMed 2003, 5:30.

    PubMed  Google Scholar 

  63. Acosta EP, Gerber JG: Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002, 18:825–834.

    Article  PubMed  CAS  Google Scholar 

  64. Lori F, Foli A, Lisziewicz J: Structured treatment interruptions as a potential alternative therapeutic regimen for HIVinfected patients: a review of recent clinical data and future prospects. J Antimicrob Chemother 2002, 50:155–160.

    Article  PubMed  CAS  Google Scholar 

  65. Ward DJ: Novel treatment strategies. http://www.medscape. com. Accessed August, 26, 2003.

  66. Powderly WG, Saag MS, Chapman S, et al.: Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999, 13:1873–1880.

    Article  PubMed  CAS  Google Scholar 

  67. Smith D, Grey P, Petoumenos K, et al.: Virological and immunological predictors of time to initial viral suppression and viral rebound in a randomised trial of combination therapy in primary HIV infection followed by treatment interruption [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  68. Lawrence J, Mayers DL, Hullsiek KH, et al.: Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003, 349:837–846.

    Article  PubMed  Google Scholar 

  69. Katlama C, Dominguez S, Duvivier C, et al.: Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097) [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.

  70. Dybul M, Nies-Kraske E, Daucher M, et al.: A randomized controlled trial of long cycle structured intermittent versus continuous ARV therapy for chronic HIV infection [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.

  71. Borkowsky W: T-cell and virologic outcomes of a progressively increasing structured treatment interruption study in chronically infected children and adolescents [abstract]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10–14, 2003.

  72. Ribaudo H, Downey G, Fischl M, et al.: Factors associated with virologic failure and their impact on treatment outcomes: an analysis of virologic failure in ACTG 388 [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  73. Abadi J, Sprecher E, Rosenberg M, et al.: Partial treatment interruption of PI-based HAART regimens in HIV-infected children [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  74. Beckerman K, Covington D, Garcia P, et al.: Association between antiretroviral therapy during pregnancy and prematurity/low birth weight [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  75. Thorne C, Newell M: Pregnancy outcome in ART-treated HIV-infected women in Europe [abstract]. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.

  76. Gerschenson M, Nguyen V, Ewings EL, et al.: Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004, 20:91–100.

    Article  PubMed  CAS  Google Scholar 

  77. Blanche S, Tardieu M, Rustin P, et al.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354:1084–1089.

    Article  PubMed  CAS  Google Scholar 

  78. Leonard EG, McComsey GA: Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003, 22:77–84.

    Article  PubMed  Google Scholar 

  79. Jaquet D, Levine M, Ortega-Rodriguez E, et al.: Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000, 14:2123–2128.

    Article  PubMed  CAS  Google Scholar 

  80. McComsey GA, Alvarez A, Jet J: Is simplification of HAART safe in HIV-infected children? First pediatric switch study [abstract]. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; February 4–8, 2001.

  81. Church JA, Mitchell WG, Gonzalez-Gomez I, et al.: Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 2001, 138:748–751.

    Article  PubMed  CAS  Google Scholar 

  82. Oleske J, Gaughan D, Mofenson L, et al.: Bone disorders in HIV-infected and -exposed children [abstract]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain; July 7–12, 2002.

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Infectious Diseases, Keck School of Medicine, University of Southern California, 1640 Marengo Street, Suite 300, 90041, Los Angeles, CA, USA

    Michael Neely MD

Authors
  1. Michael Neely MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Kovacs MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neely, M., Kovacs, A. Management of antiretroviral therapy in neonates, children, and adolescents. Curr HIV/AIDS Rep 1, 97–104 (2004). https://doi.org/10.1007/s11904-004-0014-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-004-0014-y

Keywords

Search

Navigation